<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944281</url>
  </required_header>
  <id_info>
    <org_study_id>236850</org_study_id>
    <secondary_id>iLiNS-Zinc</secondary_id>
    <nct_id>NCT00944281</nct_id>
  </id_info>
  <brief_title>Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS)</brief_title>
  <official_title>A Randomized, Double-blind, Controlled Trial in Rural Burkina Faso to Determine the Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS). Part of the iLiNS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Polytechnique de Bobo-Dioulasso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess zinc-related biochemical and functional responses among young Burkinabe children
      with a presumed high risk of zinc deficiency who receive micronutrient products containing
      different amounts of zinc, provided with or between meals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Young healthy children will be identified by periodic consensus in the study area. 3200
      infants meeting a set of eligibility criteria will be randomly assigned to receive
      lipid-based nutrient supplements (LNS) with different amounts of zinc and a placebo or zinc
      supplement from 9 to 18 months of age. The families will receive the respective supplement at
      weekly intervals and the participants undergo a morbidity evaluation weekly, anthropometric
      evaluation at 9, 12, 15 and 18 months and laboratory analyses at enrollment and at 18 months
      of age. Growth outcomes will be analyzed during the two-year follow up at 24, 30, 36 and 42
      months of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in length and length-for-age Z-score</measure>
    <time_frame>9 to 18 mo of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in weight and weight-for-age Z-score</measure>
    <time_frame>9 to 18 mo of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of diarrhea and laboratory-confirmed malaria infection</measure>
    <time_frame>9 to 18 mo of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma zinc concentration</measure>
    <time_frame>9 to 18 mo of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body composition</measure>
    <time_frame>9 to 18 mo of age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in head circumference and mid-upper arm circumference</measure>
    <time_frame>9 to 18 mo of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stunting, underweight, and wasting</measure>
    <time_frame>9 to 18 mo of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin, iron, vitamin A and iodine status</measure>
    <time_frame>9 to 18 mo of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute lower respiratory infection (ALRI)</measure>
    <time_frame>9 to 18 mo of age</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">3220</enrollment>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>LNS-Zn5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily intake of 20 g LNS containing 5 mg of zinc and a daily placebo supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LNS-Zn10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily intake of 20 g LNS containing 10 mg of zinc and a daily placebo supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LNS-Zn0</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily intake of 20 g LNS containing 0 mg of zinc and a daily placebo supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suppl-Zn5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily intake of zinc supplement containing 5 mg of zinc and 20 g LNS containing 0 mg of zinc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed intervention group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care from age 8 to 18 months. Daily consumption of LNS from age 18 to 28 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LNS-Zn5</intervention_name>
    <description>Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement</description>
    <arm_group_label>LNS-Zn5</arm_group_label>
    <other_name>Nutriset</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LNS-Zn10</intervention_name>
    <description>Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement</description>
    <arm_group_label>LNS-Zn10</arm_group_label>
    <other_name>Nutriset</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LNS-Zn0</intervention_name>
    <description>20 g of LNS containing 0 mg of zinc and a daily placebo supplement</description>
    <arm_group_label>LNS-Zn0</arm_group_label>
    <other_name>Nutriset</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Suppl-Zn5</intervention_name>
    <description>Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc</description>
    <arm_group_label>Suppl-Zn5</arm_group_label>
    <other_name>Nutriset</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  9.0 to 9.9 mo of age

        Exclusion Criteria:

          -  severe anemia

          -  severely malnourished

          -  presence of bipedal oedema

          -  severe illness

          -  congenital abnormalities

          -  chronic medical condition

          -  known HIV infection of mother or infant

          -  history of peanut allergy

          -  history of anaphylaxis or serious allergic reaction to any substance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>9 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Dewey, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth H Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Recherche en Sciences de la Sante</name>
      <address>
        <city>Bobo-Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <link>
    <url>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122242</url>
    <description>PLoS ONE: Small-quantity lipid-based nutrient supplements...</description>
  </link>
  <results_reference>
    <citation>Hess SY, Abbeddou S, Jimenez EY, Somé JW, Vosti SA, Ouédraogo ZP, Guissou RM, Ouédraogo JB, Brown KH. Small-quantity lipid-based nutrient supplements, regardless of their zinc content, increase growth and reduce the prevalence of stunting and wasting in young burkinabe children: a cluster-randomized trial. PLoS One. 2015 Mar 27;10(3):e0122242. doi: 10.1371/journal.pone.0122242. eCollection 2015.</citation>
    <PMID>25816354</PMID>
  </results_reference>
  <results_reference>
    <citation>Somé JW, Abbeddou S, Yakes Jimenez E, Hess SY, Ouédraogo ZP, Guissou RM, Vosti SA, Ouédraogo JB, Brown KH. Effect of zinc added to a daily small-quantity lipid-based nutrient supplement on diarrhoea, malaria, fever and respiratory infections in young children in rural Burkina Faso: a cluster-randomised trial. BMJ Open. 2015 Sep 11;5(9):e007828. doi: 10.1136/bmjopen-2015-007828.</citation>
    <PMID>26362661</PMID>
  </results_reference>
  <results_reference>
    <citation>Hess SY, Abbeddou S, Yakes Jimenez E, Ouédraogo JB, Brown KH. Iodine status of young Burkinabe children receiving small-quantity lipid-based nutrient supplements and iodised salt: a cluster-randomised trial. Br J Nutr. 2015 Dec 14;114(11):1829-37. doi: 10.1017/S0007114515003554. Epub 2015 Sep 28.</citation>
    <PMID>26411504</PMID>
  </results_reference>
  <results_reference>
    <citation>Abbeddou S, Yakes Jimenez E, Somé JW, Ouédraogo JB, Brown KH, Hess SY. Small-quantity lipid-based nutrient supplements containing different amounts of zinc along with diarrhea and malaria treatment increase iron and vitamin A status and reduce anemia prevalence, but do not affect zinc status in young Burkinabe children: a cluster-randomized trial. BMC Pediatr. 2017 Feb 2;17(1):46. doi: 10.1186/s12887-016-0765-9.</citation>
    <PMID>28152989</PMID>
  </results_reference>
  <results_reference>
    <citation>Hess SY, Peerson JM, Becquey E, Abbeddou S, Ouédraogo CT, Somé JW, Yakes Jimenez E, Ouédraogo JB, Vosti SA, Rouamba N, Brown KH. Differing growth responses to nutritional supplements in neighboring health districts of Burkina Faso are likely due to benefits of small-quantity lipid-based nutrient supplements (LNS). PLoS One. 2017 Aug 3;12(8):e0181770. doi: 10.1371/journal.pone.0181770. eCollection 2017.</citation>
    <PMID>28771493</PMID>
  </results_reference>
  <results_reference>
    <citation>Abbeddou S, Hess SY, Yakes Jimenez E, Somé JW, Vosti SA, Guissou RM, Ouédraogo JB, Brown KH. Comparison of methods to assess adherence to small-quantity lipid-based nutrient supplements (SQ-LNS) and dispersible tablets among young Burkinabé children participating in a community-based intervention trial. Matern Child Nutr. 2015 Dec;11 Suppl 4:90-104. doi: 10.1111/mcn.12162.</citation>
    <PMID>25521188</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>point-of-use fortification</keyword>
  <keyword>zinc supplement</keyword>
  <keyword>lipid-based nutrient supplement</keyword>
  <keyword>zinc deficiency</keyword>
  <keyword>micronutrient deficiency</keyword>
  <keyword>anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

